LFWDNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Lifeward Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$5.93−0.07 (-1.17%)
Close on Oct 19, 2026
- Market cap
- $16.58M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
38.2%−11.6 pts over 5 years
Operating margin
-89.3%+184.0 pts over 5 years
Net margin
-90.4%+205.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -14.1% | +58.7% | +38.1% | +19.4% | |
| Gross profit | +2.6% | +64.2% | +30.9% | +44.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -222.8% | -79.7% | -146.1% | |
| Return on assets | -113.4% | -49.5% | -74.6% | |
| Current ratio | 2.37 | 5.41 | 1.31 | |
| Debt to equity | 2.18 | – | – | |
| Net debt to EBITDA | 0.22× | – | – | |
| Interest coverage | -15.4× | -13.2× | – | |
| Inventory turnover | 1.8× | 0.7× | 2.2× | |
| Capex to revenue | 7.7% | 1.7% | 0.1% | |
| Diluted shares | 0M | 0M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lifeward generated $88.57M from operations and spent $169.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$88.57M
Used
$169.00K
Capital expenditure$169.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-90.4%
×Asset turnover0.83×
×Equity multiplier1.96×
=Return on equity, FY2025-146.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -90.4% | 0.83× | 1.96× | -146.1% |
| FY2024 | -112.8% | 0.55× | 1.43× | -88.6% |
| FY2023 | -159.8% | 0.20× | 1.20× | -38.6% |
| FY2022 | -355.1% | 0.07× | 1.07× | -24.8% |
| FY2021 | -213.5% | 0.10× | 1.10× | -22.9% |
| FY2020 | -295.4% | 0.17× | 1.61× | -79.7% |
| FY2019 | -319.1% | 0.25× | 3.09× | -244.4% |
| FY2018 | -331.2% | 0.35× | 6.69× | -767.0% |
| FY2017 | -318.8% | 0.28× | 4.56× | -413.1% |
| FY2016 | -553.8% | 0.20× | 1.96× | -222.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$19.91M
- Cash generatingOperating cash flow above zero-$16.83M
- Return on assets improvedROA up on the prior year-45.8% → -65.3%
- Earnings backed by cashOperating cash flow above net income-$16.83M vs -$19.91M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.08 → 1.31
- No dilutionShare count did not rise1M → 1M
- Gross margin improvedGross margin up on the prior year32.01% → 38.25%
- More efficientAsset turnover rose0.41 → 0.72